Table 2. Multivariate analysis (Cox regression) for clinical and molecular variables of DFS and OS in CN-AML patients.

Variant	DFS		OS
	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
Age#	0.32 (0.12∼0.87)	.025 *	0.37 (0.13∼1.07)	.037 *
WT1op	2.17 (0.96∼4.92)	.034 *	2.50 (1.10∼5.68)	.028 *
NPM1mt	1.68 (0.41∼6.82)	.470	0.92 (0.25∼3.40)	0.9
FLT3TKD	2.71 (0.89∼8.33)	.082	2.01 (0.55∼7.28)	.289
FLT3ITD	3.35 (1.26∼8.92)	.016 *	3.91 (1.42∼10.72)	.008 *
Risk molecular subgroups
Favorable
NPM1mt/no FLT3ITD	0.07 (0.01∼0.88)	.039 *	0.16 (0.07∼1.01)	.041 *
Unfavorable
FLT3ITD	3.35 (1.26∼8.92)	.016 *	3.91 (1.42∼10.72)	.008 *
Intermediate
Others excluding NPM1mt/no FLT3ITD and FLT3ITD	1.15 (0.25∼5.39)	.86	1.27 (0.34∼6.16)	.81

CN-AML, cytogenetically normal acute myeloid leukemia; DFS, disease-free survival; OS, overall survival; CI, confidence interval; WT1^op, WT1 overexpression.

^#age ≤60 years vs. >60 years.

*P values <.05.